Testing a similar biologic to Dupixent in healthy men
Treatments studied
This study tests whether a new injection, GLR1044, works like Dupixent® in healthy male volunteers. It helps researchers check safety and similarity before moving to larger trials.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man between 18 and 55 years old.
- Your weight is between 120 and 188 pounds, with a BMI between 19 and 26.
- You are in good general health with no significant medical conditions, as determined by study doctors.
- You have no history of tuberculosis or exposure to it.
- You agree to use reliable birth control for yourself and your partner during the study and for 6 months after.
- You have not used certain medications or participated in other drug trials recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a single dose of a new medicine called PG-033 in healthy adults. It checks how the drug moves through the body and how food affects it, to find the safest starting dose for future studies.
This trial tests a new biologic medicine (GS101) against an approved treatment (Dupixent) for conditions like atopic dermatitis. It is looking for healthy volunteers to compare how the body processes each drug after an injection under the skin.
This trial tests a new version of Dupixent® (called CKD-706) to see how it compares to the approved medicine in healthy adults. It's a first step to make sure the new medicine works similarly and is safe.
This study compares a new injection (GS101) against an approved medicine (Dupixent) for people with moderate-to-severe eczema. The goal is to see if GS101 works as well or better.
This trial tests if a new medication, QL2108, works as well as the approved drug Dupixent for adults with moderate-to-severe atopic dermatitis (eczema). You may be able to join if you've had eczema for at least a year and have active symptoms covering a large area of your body.
This study compares a new injectable medicine (IBI3027) to an approved one (Dupilumab) for people with moderate-to-severe eczema. If you join, you'll receive one of the two treatments to see if the new one works as well for reducing itching and skin symptoms.
Hear when a new Biosimilarity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.